1.075USD-3.15%Mkt Cap: 46.26M USDP/E: —Last update: 2026-06-01
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap46.26M USD
Enterprise Value44.98M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-13.06M USD
Revenue/Share—
Last Price1.075 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.41
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-3.99
EPS (TTM)-0.34
EPS (Forward)-0.32
52W Range
0.780012% of range3.150
52W High3.150 USD
52W Low0.7800 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE126.02%
ROA-411.19%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.79M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-5.88%
Net Debt-1.93M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio0.24
Quick Ratio0.22
Book Value/Sh-0.2730 USD
Cash/Share0.0450 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)12.00 USD
Target Range12.00 USD – 12.00 USD
# Analysts1
Ownership
Shares Out.43.03M
Float14.11M
Insiders60.61%
Institutions12.15%
Short Interest
Short Ratio2.4d
Short % Float0.56%
Short % Out.0.22%
Shares Short94.14K
Short (prev mo.)265.81K
Technical
SMA 501.369 (-21.4%)
SMA 2001.427 (-24.7%)
Beta0.98
S&P 52W Chg27.94%
Avg Vol (30d)32.74K
Avg Vol (10d)30.34K
Technical Indicators
RSI (14)35.7
MACD-0.0932
MACD Signal-0.0886
MACD Hist.-0.0046
BB Upper1.516 USD
BB Middle1.229 USD
BB Lower0.9408 USD
BB Width46.85%
ATR (14)0.1184 USD
Vol Ratio (20d)0.22x